tumour vaccines
Recently Published Documents


TOTAL DOCUMENTS

32
(FIVE YEARS 4)

H-INDEX

6
(FIVE YEARS 1)

2021 ◽  
Vol 14 (5) ◽  
pp. 101040 ◽  
Author(s):  
Amaia Vergara Bermejo ◽  
Karen Nørgaard Nielsen ◽  
Peter Johannes Holst

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Keman Cheng ◽  
Ruifang Zhao ◽  
Yao Li ◽  
Yingqiu Qi ◽  
Yazhou Wang ◽  
...  

AbstractAn effective tumor vaccine vector that can rapidly display neoantigens is urgently needed. Outer membrane vesicles (OMVs) can strongly activate the innate immune system and are qualified as immunoadjuvants. Here, we describe a versatile OMV-based vaccine platform to elicit a specific anti-tumor immune response via specifically presenting antigens onto OMV surface. We first display tumor antigens on the OMVs surface by fusing with ClyA protein, and then simplify the antigen display process by employing a Plug-and-Display system comprising the tag/catcher protein pairs. OMVs decorated with different protein catchers can simultaneously display multiple, distinct tumor antigens to elicit a synergistic antitumour immune response. In addition, the bioengineered OMVs loaded with different tumor antigens can abrogate lung melanoma metastasis and inhibit subcutaneous colorectal cancer growth. The ability of the bioengineered OMV-based platform to rapidly and simultaneously display antigens may facilitate the development of these agents for personalized tumour vaccines.


Nature ◽  
2016 ◽  
Vol 532 (7600) ◽  
pp. 425-425 ◽  
Author(s):  
Heidi Ledford
Keyword(s):  

2014 ◽  
Vol 12 (2) ◽  
pp. 64-64
Author(s):  
David Killock
Keyword(s):  

2013 ◽  
Vol 20 (5) ◽  
pp. 367-368 ◽  
Author(s):  
George Rakovich ◽  
Lise Tremblay

Historically, all non-small cell lung cancers were essentially grouped together and considered to be a single disease. However, it is now recognized that non-small cell lung cancer actually comprises a genetically diverse group of tumours. This, in turn, affords a new opportunity for the development of effective treatments tailored to individual tumours and patients. Advances in molecular biology have made possible the development of drugs against specific molecular targets on cancer cells, most notably the tyrosine kinase inhibitors. The relevant literature and current practice guidelines are discussed. In addition, other related areas of active investigation, including tumour vaccines and pharmacogenetics, are briefly reviewed.


Sign in / Sign up

Export Citation Format

Share Document